A Study Evaluating the Effects of Ataciguat (HMR1766) on Aortic Valve Calcification
A Study Evaluating the Effects of Ataciguat (HMR1766) on Aortic Valve Calcification
The primary objective of the current study is to determine whether Ataciguat (HMR1766) slows
 progression of valve calcification in patients with moderate calcific aortic valve stenosis.
 Secondary and tertiary objectives are to determine whether Ataciguat slows progression of
 aortic valve function, reduces systemic inflammation, and prevents left ventricular
 dysfunction in patients with moderate calcific aortic valve stenosis.
Patients with Moderate Calcific Aortic Valve Stenosis may be eligible for enrollment in this
 study. Participation lasts 12 months, which includes a total of 3 study visits
 (baseline/screening visit, 6 month follow up visit and 12 month follow up visit). During each
 visit, a blood sample will be taken along with other research related tests (Orthostatic
 Tolerance Standing Test, CT Scan, Echocardiogram, DEXA Scan). Qualifying Participants will be
 supplied with 6 months worth of study medication or placebo during visits 1
 (baseline/screening visit) and 2 (6 month follow up visit) in which they will take at home
 daily with food. On visit 3 (12 month follow up visit), any remaining study medication or
 placebo will be returned to study staff.
Inclusion Criteria

 1. Age > 50 years

 2. Male or female sex

 3. Aortic valve area greater than 1.0 cm2 but less than 2.0 cm2

 4. Aortic valve calcium levels greater than 300 AU from chest CT

 5. Ejection fraction >50%

 Exclusion Criteria

 1. Orthostatic intolerance or symptomatic hypotension prior to study or during study
 visits

 2. Positive pregnancy test during screening visit

 3. Nitrate use or α-antagonist medication use within 24 hours

 4. Systolic blood pressure <110 mm Hg

 5. Mean systemic arterial pressure <75 mm Hg

 6. Severe mitral or aortic regurgitation

 7. Retinal or optic nerve problems

 8. Recent (≤30 days) acute coronary syndrome

 9. Oxygen saturation <90% on room air

 10. Congenital valve disease

 11. Hepatic dysfunction/elevated liver enzymes

 12. Prescription of drugs known to alter NO-sGC-cGMP signaling (sildenafil, nitrates,
 etc.)

 13. Prescription of Warfarin (Coumadin) for chronic anticoagulation

 14. Concomitant participation in other trials at Mayo Clinic or elsewhere

 15. Use of phenytoin or related compounds for any indication

 16. Chronic midazolam treatment for any indication

 17. Use of monoamine oxidase inhibitors for any indication

 18. Use of anti-diabetic drugs in the sulfonylurea family